Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02792517 · ClinicalTrials.gov registry record · Phase 1
Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females
A Phase 1 study of Headache, Migraine, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 4
- Study locations
NCT02792517 is a Phase 1 study of Headache, Migraine that has completed, run by Amgen. The registered enrollment target is 41 participants, below the 248-participant average among 7 other Headache, Migraine trials with a reported enrollment target (83% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT02792517, a Phase 1 study of Headache, Migraine, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 4
- Study locations
Study Summary
A pharmacokinetic drug interaction study of erenumab and an oral contraceptive containing progestin and estrogen.
Conditions Studied
Interventions
- DRUG Erenumab
- DRUG Ethynil Estradiol/Norgestimate Oral Contraceptive
Study Locations (4)
California
- Research Site - Anaheim
- Research Site - Cypress
Texas
- Research Site - Dallas
Wisconsin
- Research Site - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2016-02-12 |
| Est. Completion | 2016-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02792517
The ClinicalTrials.gov registry entry for NCT02792517 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 248-participant average among 7 other Headache, Migraine trials with a reported enrollment target (83% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Headache, Migraine appearing as the primary indexed condition, and to 2 interventions - of which Erenumab is the first listed.
NCT02792517 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Texas, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT02792517 about?
NCT02792517 is a clinical study titled "Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females". A pharmacokinetic drug interaction study of erenumab and an oral contraceptive containing progestin and estrogen.
What is the current status of trial NCT02792517?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2016-02-12. Estimated completion is 2016-09-09.
What conditions does trial NCT02792517 study?
This clinical trial studies the following conditions: Headache, Migraine.
What interventions are being tested in trial NCT02792517?
The interventions under investigation include: Erenumab (DRUG), Ethynil Estradiol/Norgestimate Oral Contraceptive (DRUG).
Who is sponsoring clinical trial NCT02792517?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02792517 being conducted?
This trial has 4 study locations across California, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Headache, Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Mind Body Balance for Pediatric Migraine
RECRUITING · NA
-
Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies
ACTIVE NOT RECRUITING · Phase 4
-
Feasibility of Using Holographic Memory Resolution® (HMR) in Patients/Clients With Pain
COMPLETED · NA
-
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
COMPLETED · NA
-
Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.